India · Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 150.85 billion. The enterprise value is 136.69 billion.
| Market Cap | 150.85B |
| Enterprise Value | 136.69B |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | Feb 18, 2026 |
Share Statistics
NATCO Pharma has 179.11 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | 179.11M |
| Shares Outstanding | 179.11M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 29.46% |
| Owned by Institutions (%) | 10.90% |
| Float | 83.55M |
Valuation Ratios
The trailing PE ratio is 10.63 and the forward PE ratio is 20.90.
| PE Ratio | 10.63 |
| Forward PE | 20.90 |
| PS Ratio | 3.70 |
| PB Ratio | 1.64 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | 10.93 |
| P/OCF Ratio | 8.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.22, with an EV/FCF ratio of 9.91.
| EV / Earnings | 9.64 |
| EV / Sales | 3.35 |
| EV / EBITDA | 9.22 |
| EV / EBIT | 10.71 |
| EV / FCF | 9.91 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.01 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.52 |
| Interest Coverage | 33.51 |
Financial Efficiency
Return on equity (ROE) is 16.85% and return on invested capital (ROIC) is 16.79%.
| Return on Equity (ROE) | 16.85% |
| Return on Assets (ROA) | 7.80% |
| Return on Invested Capital (ROIC) | 16.79% |
| Return on Capital Employed (ROCE) | 13.09% |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | 9.71M |
| Profits Per Employee | 3.38M |
| Employee Count | 4,199 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0.79 |
Taxes
In the past 12 months, NATCO Pharma has paid 1.19 billion in taxes.
| Income Tax | 1.19B |
| Effective Tax Rate | 7.73% |
Stock Price Statistics
The stock price has decreased by -4.47% in the last 52 weeks. The beta is 0.19, so NATCO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -4.47% |
| 50-Day Moving Average | 1,073.07 |
| 200-Day Moving Average | 924.48 |
| Relative Strength Index (RSI) | 21.36 |
| Average Volume (20 Days) | 977,619 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 40.78 billion and earned 14.19 billion in profits. Earnings per share was 79.20.
| Revenue | 40.78B |
| Gross Profit | 33.88B |
| Operating Income | 12.30B |
| Pretax Income | 15.37B |
| Net Income | 14.19B |
| EBITDA | 14.37B |
| EBIT | 12.30B |
| Earnings Per Share (EPS) | 79.20 |
Balance Sheet
The company has 21.29 billion in cash and 7.14 billion in debt, with a net cash position of 14.15 billion or 79.01 per share.
| Cash & Cash Equivalents | 21.29B |
| Total Debt | 7.14B |
| Net Cash | 14.15B |
| Net Cash Per Share | 79.01 |
| Equity (Book Value) | 92.21B |
| Book Value Per Share | 514.92 |
| Working Capital | 33.71B |
Cash Flow
In the last 12 months, operating cash flow was 17.68 billion and capital expenditures -3.88 billion, giving a free cash flow of 13.80 billion.
| Operating Cash Flow | 17.68B |
| Capital Expenditures | -3.88B |
| Depreciation & Amortization | 2.07B |
| Net Borrowing | 4.24B |
| Free Cash Flow | 13.80B |
| FCF Per Share | 77.05 |
Margins
Gross margin is 83.07%, with operating and profit margins of 30.16% and 34.78%.
| Gross Margin | 83.07% |
| Operating Margin | 30.16% |
| Pretax Margin | 37.70% |
| Profit Margin | 34.78% |
| EBITDA Margin | 35.22% |
| EBIT Margin | 30.16% |
| FCF Margin | 33.84% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.59%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 0.59% |
| Dividend Growth (YoY) | -16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.36% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.59% |
| Earnings Yield | 9.40% |
| FCF Yield | 9.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NATCO Pharma is 1,021.22, which is 21.26% higher than the current price. The consensus rating is "Hold".
| Price Target | 1,021.22 |
| Price Target Difference | 21.26% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 3.06% |
| EPS Growth Forecast (3Y) | -6.57% |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |